Nycomed posts strong first quarter financial results

Nycomed has published its financial report for the first quarter of 2011, during which it experienced signs of strong annual growth.

The pharmaceutical company's net turnover for the three months came to 923.7 million euros (806.27 million pounds), which represented a 19.9 per cent year-on-year increase.

According to Nycomed, growth has been driven by its performance in emerging markets, where it is demonstrating an above-average expansion rate, while rising sales of its key products have also contributed.

The last quarter also saw Nycomed receive a 131.3 million euro payment from partner Forest Laboratories after US approval was secured for the chronic obstructive pulmonary disease drug Daxas.

These strong results come in the same month that Takeda announced plans to acquire Nycomed in a deal worth 9.6 billion euros.

Nycomed chief executive officer Hakan Bjorklund said this move will "bring together Takeda's track record of innovation and Nycomed's efficient commercialisation and manufacturing infrastructure to create a global player able to meet the needs of patients and healthcare providers around the world".